Clinical Trial Update: A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial of VLX103 for alcoholic steatohepatitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcoholic Steatohepatitis
• Hepatic Steatosis

Drugs mentioned

• VLX103

Snippet

Sponsor: Gyongyi Szabo | Conditions: Hepatic Steatosis | Phase 1 | Status: WITHDRAWN